Header and Body 4


  • Higher compliance – Eliminates multiple hospital visits due to single injection and lowers costs
  • Reduces risk of metastasis – Single injection reduces tumor microenvironment perturbations
  • Programmable release – Can easily control the time of delayed drug release on the order of days, weeks or months by changing the lactide:glycolide ratio
  • Versatile Platform – Encapsulates and releases any type of multi-dose therapeutic payload
  • Low toxicity – Microdevices can be manufactured from multiple FDA-approved and commercially available biocompatible and biodegradable polymers